title: [A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum].
abstract: Survival of patients with advanced gastric cancer with Krukenberg's tumor is poor. We report the case of a good response in a 37-year-old woman who had type 4 gastric cancer, diagnosed after the operation of Krukenberg's tumor, and then was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with a low-dose cisplatinum (CDDP). Endoscopic gastric biopsy showed signet-ring cell adenocarcinoma and moderately differentiated tubular adenocarcinoma, and computed tomography (CT) showed the para-aortic lymph node metastasis before the chemotherapy. The patient was treated with two courses of TS-1 (100 mg/day, day 1-21) plus CDDP (10 mg/m2, day 1-5, 8-12, 15-19) with two-week interval. After the first course, gastric biopsy did not show any cancer cells and lymph node metastasis had disappeared. Serum CA19-9 decreased gradually week by week during the chemotherapy, even during the washout period after the first course, and was normalized after two courses. This case suggests that the combination of TS-1 and low-dose CDDP is effective against type 4 advanced gastric cancer.
authors.affiliation: Dept. of Internal Medicine, Keio University.
authors.forename: Yasutada
authors.initials: Y
authors.lastname: Akiba
authors.forename: Chikako
authors.initials: C
authors.lastname: Watanabe
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takada
authors.forename: Kotaro
authors.initials: K
authors.lastname: Naito
authors.forename: Daisuke
authors.initials: D
authors.lastname: Aoki
authors.forename: Makio
authors.initials: M
authors.lastname: Mukai
authors.forename: Shinzo
authors.initials: S
authors.lastname: Kato
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Hibi
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Ishii
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007725:Krukenberg Tumor / Q000601:surgery*; D007912:Lentinan / Q000008:administration & dosage; D009378:Neoplasms, Multiple Primary; D017294:Ondansetron / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000601:surgery*; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D007912:Lentinan; D017294:Ondansetron; D010094:Oxonic Acid; D002945:Cisplatin